


ACCESSING THE RIGHT TREATMENT FOR IgG4-RD

Identifying the right care plan is **CHALLENGING** for IgG4-RD patients.



There are no FDA-approved treatments for their disease, so patients must rely on off-label medications.

**INNOVATIVE TREATMENTS
ARE ON THE HORIZON.**



But as new, FDA-approved treatments become available, utilization management **TACTICS POSE A THREAT TO PATIENT ACCESS.**



**POLICIES MUST PROTECT
IgG4-RD PATIENTS**

from harmful delays or denials.



Insurers' tactics shouldn't stand between IgG4-RD patients and

**TIMELY
TREATMENT.**



AfPA